Trial Profile

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plozasiran (Primary)
Indications Hypertriglyceridaemia
Focus Registrational; Therapeutic Use
Acronyms SHASTA-3
Sponsors Arrowhead Pharmaceuticals

Most Recent Events

02 Sep 2024 Trial design presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.
09 Jul 2024 Planned initiation date changed from 1 May 2024 to 1 Jul 2024.
27 Apr 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com